News blog

Alltracel Pharmaceuticals

  • BY: Andrew Hore |
  • POSTED: 21/01/2008 |

Wound and skin care products developer Alltracel Pharmaceuticals says it is talking to a possible bidder.

It is described as a “very preliminary approach”. The shares rose 0.625p to 9.875p.

In a trading statement, Alltracel said that the integration of oral care and sports bandage supplier Synpart had progressed well and it is expected to a key factor for revenue growth in 2008.

In July 2007 the company’s healthcare technology business, Nanopeutics, signed a licensing agreement with HemCon Medical Technologies which could lead to products being launched in 2008. It also has a technology development agreement with wound care company ConvaTec. If the agreement progresses as planned it could lead to an exclusive royalty bearing license and supply agreement between the two companies.

Alltracel has formed a UK-based contract research joint venture with Canadian research organisation Venn Life Sciences.

The 2007 results are due to be reported in early April.

© 2024 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Browse by issue
All issues
Popular tags
All tags

betbrokers, financial, gold, health, leisure, media, mobile, resources, services, technology

AIM Micro feeds

Keep up to date with articles published at AIMMicro.com. Subscribe to AIM Micro RSS Feeds